Platelet-activating factor receptor knockout mice are protected from MPTP-induced dopaminergic degeneration

Beom Keun Kim, Eun Joo Shin, Hyoung Chun Kim, Yoon Hee Chung, Duy Khanh Dang, Bae Dong Jung, Dae Hun Park, Myung Bok Wie, Won-Ki Kim, Takao Shimizu, Toshitaka Nabeshima, Ji Hoon Jeong

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Platelet-activating factor (PAF), a potent mediator of inflammatory and immune responses, plays various roles in neuronal functions. However, little is known about the role of PAF/platelet-activating factor receptor (PAF-R) in Parkinson's disease. Treatment with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) resulted in significant increases in PAF species in the striatum of wild-type mice. These increases paralleled PAF-R gene expression in wild-type mice. Although nuclear factor kappa B (NF-κB) DNA-binding activity was increased significantly in MPTP-treated wild-type mice, this increase was not significant in PAF-R antagonist ginkgolide B (GB)-treated mice or PAF-R knockout (PAF-R-/-) mice. Pyrrolidine dithiocarbamate (PDTC), an NF-κB inhibitor, significantly ameliorated the dopaminergic deficits induced by MPTP in wild-type mice. MPTP treatment significantly increased oxidative damage, the immunoreactivity of ionized calcium binding adaptor molecule 1 (Iba-1)-positive microglial cells, and microglial differentiation of the M1 type in the striatum of wild-type mice. Consistently, PDTC significantly attenuated MPTP-induced behavioral impairments in wild-type mice. However, dopaminergic deficits, oxidative damage, reactive microglial cells, and behavioral impairments induced by MPTP were not significantly observed in GB-treated mice or PAF-R -/- mice. PDTC did not significantly alter the attenuations evident in MPTP-treated PAF-R-/- mice, indicating that NF-κB is a critical target for neurotoxic modulation of PAF-R. We propose for the first time that PAF/PAF-R can mediate dopaminergic degeneration via an NF-κB-dependent signaling process.

Original languageEnglish
Pages (from-to)121-132
Number of pages12
JournalNeurochemistry International
Volume63
Issue number3
DOIs
Publication statusPublished - 2013 Jun 27

Fingerprint

Platelet Activating Factor
Knockout Mice
ginkgolide B
NF-kappa B
platelet activating factor receptor
4-phenyl-1,2,3,6-tetrahydropyridine
vpr Genes
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
Parkinson Disease
Cell Differentiation

Keywords

  • Dopamine
  • Microglia
  • Nuclear factor kappa B
  • Oxidative damage
  • Parkinson's disease
  • Platelet-activating factor receptor
  • Striatum

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Cell Biology

Cite this

Kim, B. K., Shin, E. J., Kim, H. C., Chung, Y. H., Dang, D. K., Jung, B. D., ... Jeong, J. H. (2013). Platelet-activating factor receptor knockout mice are protected from MPTP-induced dopaminergic degeneration. Neurochemistry International, 63(3), 121-132. https://doi.org/10.1016/j.neuint.2013.05.010

Platelet-activating factor receptor knockout mice are protected from MPTP-induced dopaminergic degeneration. / Kim, Beom Keun; Shin, Eun Joo; Kim, Hyoung Chun; Chung, Yoon Hee; Dang, Duy Khanh; Jung, Bae Dong; Park, Dae Hun; Wie, Myung Bok; Kim, Won-Ki; Shimizu, Takao; Nabeshima, Toshitaka; Jeong, Ji Hoon.

In: Neurochemistry International, Vol. 63, No. 3, 27.06.2013, p. 121-132.

Research output: Contribution to journalArticle

Kim, BK, Shin, EJ, Kim, HC, Chung, YH, Dang, DK, Jung, BD, Park, DH, Wie, MB, Kim, W-K, Shimizu, T, Nabeshima, T & Jeong, JH 2013, 'Platelet-activating factor receptor knockout mice are protected from MPTP-induced dopaminergic degeneration', Neurochemistry International, vol. 63, no. 3, pp. 121-132. https://doi.org/10.1016/j.neuint.2013.05.010
Kim, Beom Keun ; Shin, Eun Joo ; Kim, Hyoung Chun ; Chung, Yoon Hee ; Dang, Duy Khanh ; Jung, Bae Dong ; Park, Dae Hun ; Wie, Myung Bok ; Kim, Won-Ki ; Shimizu, Takao ; Nabeshima, Toshitaka ; Jeong, Ji Hoon. / Platelet-activating factor receptor knockout mice are protected from MPTP-induced dopaminergic degeneration. In: Neurochemistry International. 2013 ; Vol. 63, No. 3. pp. 121-132.
@article{71f956889ac8479090a5d17d75900b75,
title = "Platelet-activating factor receptor knockout mice are protected from MPTP-induced dopaminergic degeneration",
abstract = "Platelet-activating factor (PAF), a potent mediator of inflammatory and immune responses, plays various roles in neuronal functions. However, little is known about the role of PAF/platelet-activating factor receptor (PAF-R) in Parkinson's disease. Treatment with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) resulted in significant increases in PAF species in the striatum of wild-type mice. These increases paralleled PAF-R gene expression in wild-type mice. Although nuclear factor kappa B (NF-κB) DNA-binding activity was increased significantly in MPTP-treated wild-type mice, this increase was not significant in PAF-R antagonist ginkgolide B (GB)-treated mice or PAF-R knockout (PAF-R-/-) mice. Pyrrolidine dithiocarbamate (PDTC), an NF-κB inhibitor, significantly ameliorated the dopaminergic deficits induced by MPTP in wild-type mice. MPTP treatment significantly increased oxidative damage, the immunoreactivity of ionized calcium binding adaptor molecule 1 (Iba-1)-positive microglial cells, and microglial differentiation of the M1 type in the striatum of wild-type mice. Consistently, PDTC significantly attenuated MPTP-induced behavioral impairments in wild-type mice. However, dopaminergic deficits, oxidative damage, reactive microglial cells, and behavioral impairments induced by MPTP were not significantly observed in GB-treated mice or PAF-R -/- mice. PDTC did not significantly alter the attenuations evident in MPTP-treated PAF-R-/- mice, indicating that NF-κB is a critical target for neurotoxic modulation of PAF-R. We propose for the first time that PAF/PAF-R can mediate dopaminergic degeneration via an NF-κB-dependent signaling process.",
keywords = "Dopamine, Microglia, Nuclear factor kappa B, Oxidative damage, Parkinson's disease, Platelet-activating factor receptor, Striatum",
author = "Kim, {Beom Keun} and Shin, {Eun Joo} and Kim, {Hyoung Chun} and Chung, {Yoon Hee} and Dang, {Duy Khanh} and Jung, {Bae Dong} and Park, {Dae Hun} and Wie, {Myung Bok} and Won-Ki Kim and Takao Shimizu and Toshitaka Nabeshima and Jeong, {Ji Hoon}",
year = "2013",
month = "6",
day = "27",
doi = "10.1016/j.neuint.2013.05.010",
language = "English",
volume = "63",
pages = "121--132",
journal = "Neurochemistry International",
issn = "0197-0186",
publisher = "Elsevier Limited",
number = "3",

}

TY - JOUR

T1 - Platelet-activating factor receptor knockout mice are protected from MPTP-induced dopaminergic degeneration

AU - Kim, Beom Keun

AU - Shin, Eun Joo

AU - Kim, Hyoung Chun

AU - Chung, Yoon Hee

AU - Dang, Duy Khanh

AU - Jung, Bae Dong

AU - Park, Dae Hun

AU - Wie, Myung Bok

AU - Kim, Won-Ki

AU - Shimizu, Takao

AU - Nabeshima, Toshitaka

AU - Jeong, Ji Hoon

PY - 2013/6/27

Y1 - 2013/6/27

N2 - Platelet-activating factor (PAF), a potent mediator of inflammatory and immune responses, plays various roles in neuronal functions. However, little is known about the role of PAF/platelet-activating factor receptor (PAF-R) in Parkinson's disease. Treatment with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) resulted in significant increases in PAF species in the striatum of wild-type mice. These increases paralleled PAF-R gene expression in wild-type mice. Although nuclear factor kappa B (NF-κB) DNA-binding activity was increased significantly in MPTP-treated wild-type mice, this increase was not significant in PAF-R antagonist ginkgolide B (GB)-treated mice or PAF-R knockout (PAF-R-/-) mice. Pyrrolidine dithiocarbamate (PDTC), an NF-κB inhibitor, significantly ameliorated the dopaminergic deficits induced by MPTP in wild-type mice. MPTP treatment significantly increased oxidative damage, the immunoreactivity of ionized calcium binding adaptor molecule 1 (Iba-1)-positive microglial cells, and microglial differentiation of the M1 type in the striatum of wild-type mice. Consistently, PDTC significantly attenuated MPTP-induced behavioral impairments in wild-type mice. However, dopaminergic deficits, oxidative damage, reactive microglial cells, and behavioral impairments induced by MPTP were not significantly observed in GB-treated mice or PAF-R -/- mice. PDTC did not significantly alter the attenuations evident in MPTP-treated PAF-R-/- mice, indicating that NF-κB is a critical target for neurotoxic modulation of PAF-R. We propose for the first time that PAF/PAF-R can mediate dopaminergic degeneration via an NF-κB-dependent signaling process.

AB - Platelet-activating factor (PAF), a potent mediator of inflammatory and immune responses, plays various roles in neuronal functions. However, little is known about the role of PAF/platelet-activating factor receptor (PAF-R) in Parkinson's disease. Treatment with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) resulted in significant increases in PAF species in the striatum of wild-type mice. These increases paralleled PAF-R gene expression in wild-type mice. Although nuclear factor kappa B (NF-κB) DNA-binding activity was increased significantly in MPTP-treated wild-type mice, this increase was not significant in PAF-R antagonist ginkgolide B (GB)-treated mice or PAF-R knockout (PAF-R-/-) mice. Pyrrolidine dithiocarbamate (PDTC), an NF-κB inhibitor, significantly ameliorated the dopaminergic deficits induced by MPTP in wild-type mice. MPTP treatment significantly increased oxidative damage, the immunoreactivity of ionized calcium binding adaptor molecule 1 (Iba-1)-positive microglial cells, and microglial differentiation of the M1 type in the striatum of wild-type mice. Consistently, PDTC significantly attenuated MPTP-induced behavioral impairments in wild-type mice. However, dopaminergic deficits, oxidative damage, reactive microglial cells, and behavioral impairments induced by MPTP were not significantly observed in GB-treated mice or PAF-R -/- mice. PDTC did not significantly alter the attenuations evident in MPTP-treated PAF-R-/- mice, indicating that NF-κB is a critical target for neurotoxic modulation of PAF-R. We propose for the first time that PAF/PAF-R can mediate dopaminergic degeneration via an NF-κB-dependent signaling process.

KW - Dopamine

KW - Microglia

KW - Nuclear factor kappa B

KW - Oxidative damage

KW - Parkinson's disease

KW - Platelet-activating factor receptor

KW - Striatum

UR - http://www.scopus.com/inward/record.url?scp=84879208877&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879208877&partnerID=8YFLogxK

U2 - 10.1016/j.neuint.2013.05.010

DO - 10.1016/j.neuint.2013.05.010

M3 - Article

C2 - 23743065

AN - SCOPUS:84879208877

VL - 63

SP - 121

EP - 132

JO - Neurochemistry International

JF - Neurochemistry International

SN - 0197-0186

IS - 3

ER -